Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged > 65 years with advanced pancreatic cancer (APC).

Hasan Rehman,Jeffrey Chi,Nausheen Hakim,Shreya Prasad-Goyal,Coral Olazagasti,Jyothi Jose,Linda Moriarty,Wasif M. Saif

Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged > 65 years with advanced pancreatic cancer (APC).

2020

Hasan Rehman
Jeffrey Chi
Nausheen Hakim
Shreya Prasad-Goyal
Coral Olazagasti
Jyothi Jose
Linda Moriarty
Wasif M. Saif

705Background: Treatment with gemcitabine/nab-paclitaxel confers a survival benefit over gemcitabine monotherapy in APC. However, such treatment can be associated with significant toxicities especi...

Keywords:

Pancreatic cancer
Gemcitabine
Internal medicine
Oncology
Medicine
Nab-paclitaxel
Regimen
Pathology
in patient
survival benefit

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations